NUCALA (Mepolizumab) Asthma Research Study Update
Updated: Jun 10, 2019
Since May 2017, the unit has been working on a study which observes how patients with severe Asthma are responding to Mepolizumab (Nucala) – a new drug which tries to reduce Asthma attacks therefore reducing the amount of medication patients take to control their Asthma.
We have a regular Wednesday morning clinic where patients are given the Nucala injection. Through this clinic, we have been able to enrol 17 patients in to the Nucala study overall, making us the top recruiters in the world! We are also conducting an audit alongside the Nucala clinic which involves taking blood samples and performing various lung function tests.
Results from the Asthma Control Questionnaire show that in the first 3 months of receiving the treatment, most patients have reported that their symptoms have improved. Patients have reported that they are now able to do things that they previously struggled to do.
Photo (By Glenn Hearson): Charlotte Dobson Clinical Trials Assistant), Hayley Crofts (Patient), Tina Wilkinson (Clinical Trials Assistant)
Hayley, one of the patients taking part in both the audit and the study stated; “My quality of life has improved in general since starting the treatment. My breathing is better, I am able to sleep better and I am now able to exercise more”.
We will continue to collect data for the Nucala study over the next two years. We would like to thank all of the patients involved in the study and the audit and thank everyone for their continued support
We will continue to collect data for the Nucala study over the next two years. We would like to thank all of the patients involved in the study and the audit and thank everyone for their continued support.